Superhydrophobic Heart Valve Prosthesis

超疏水人工心脏瓣膜

• 批准号: 9534731
• 负责人: Lakshmi Prasad Dasi
• 金额: $ 71.9万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9534731
• 关键词: Address; Anticoagulation; Area; Artificial Heart; Biocompatible Materials; Biology; Biomechanics; Biomedical Engineering; Bioprosthesis device; Blood; Blood Platelets; Cardiovascular system; Catheters; Cells; Cessation of life; Characteristics; Clinical; Devices; Engineering; Environment; Freedom; Goals; Grant; Heart Valve Prosthesis; Heart Valves; Hemorrhage; Human; Image; In Vitro; Industry; Lead; Length; Leukocytes; Life; Liquid substance; Mechanics; Medical; Methods; Microfluidics; Operative Surgical Procedures; Patients; Performance; Pilot Projects; Plague; Platelet Activation; Polymers; Procedures; Research; Research Personnel; Risk; Saint Jude Children' s Research Hospital; Stents; Stress; Surface; Surgeon; Techniques; Technology; Testing; Thoracic Surgeon; Thromboembolism; Thrombus; Tissues; Training; Whole Blood; Work; base; biomaterial compatibility; calcification; control theory; experience; experimental study; hemodynamics; immunogenic; implantation; improved; in vivo; in vivo Model; in vivo evaluation; indexing; innovation; left ventricular assist device; macrophage; materials science; member; minimally invasive; monocyte; nanoengineering; nanoscale; novel; pericardial sac; pyrolytic carbon; response; shear stress; valve replacement

Project Summary: All present day prosthetic heart valves suffer from complications. Mechanical heart valves (HVs) require life-long anti-coagulation therapy, while bioprosthetic heart valves based on fixed tissue are plagued with durability, immunogenic and calcification issues. Superhydrophobic (SH) bileaflet mechanical heart valves with vortex generator (VG) technology promise to eliminate the need for anti-coagulation therapy. Our lab has developed a SH bileaflet mechanical heart valve (BMHV) with VGs that drastically improve surface hemocompatibility as well as eliminate turbulent stresses, thus reducing platelet activation. Preliminary work has shown that SH surfaces remarkably reduced thrombogenic potential relative to plain pyrolytic carbon leaflets. Further, we have already demonstrated the feasibility of manufacturing BMHVs and assembling them with VGs into an implantable BMHV. The present R01 study aims to gauge the efficacy of SH BMHV with VG as a potential alternative to current heart valve technology by fine tuning material composition and processing to meet the durability and antithrombogenic requirements for heart valves. Our central hypothesis is: superhydrophobic BMHVs with vortex generator flow control technology will require significantly less anti-coagulation therapy. This is tested in three aims. Aim 1 focuses on elucidating the effects of leaflet composition and processing on hemocompatibility while optimizing the strength and hemocompatibility of the coating. Aim 2 quantifies heart valve hemodynamic performance of SH with VG BMHVs to identify the ideal SH+VG configuration for superior hemodynamics and minimum blood damage. Aim 3 focuses on understanding the in vivo hemocompatibility of SH with VG BMHV in a pilot ovine study. This proposal is led by Dr. Lakshmi Prasad Dasi, who is a well trained young investigator with expertise in heart valve engineering and cardiovascular biomechanics, and inventor of several heart valve technologies including VGs and novel biomolecule polymer leaflets. Multi-PIs are Dr. Kota, who is an established superhydrophobic materials expert; Dr. Popat whose expertise lies in bio-compatibility and surface nano-engineering. Co-Is include Dr. Brueur, Dr. Bark, Dr. Crestanello, Dr. Shinoka, and Dr. Hor who form an experienced team with expertise in in-vivo models, platelet biology, surgery, and imaging. If the proposed work demonstrates that SH with VG BMHVs do not require anti-coagulation, elicit excellent hemodynamics, and are durable, this R01 grant may lead to breakthrough technology for mechanical HVs that require little or no anticoagulation.

项目摘要： 所有当今的假肢心脏瓣膜都有并发症。机械心脏阀（HVS）需要终身 抗凝治疗，而基于固定组织的生物假发瓣膜困扰着耐用性， 免疫原性和钙化问题。超疏水（SH）Bileaflet机械心脏瓣膜 发电机（VG）的技术有望消除对抗癌疗法的需求。我们的实验室已经开发了 Sh Bileaflet机械心脏阀（BMHV），其VG也极大地改善了表面血液相容性 由于消除了湍流应力，从而减少了血小板激活。初步工作表明SH表面 相对于普通的热解碳小叶，血栓形成潜力明显降低。此外，我们已经 证明了制造BMHV并将VG组装成可植入的BMHV的可行性。 目前的R01研究旨在衡量SH BMHV的功效，以VG作为当前心脏的潜在替代方案 通过微调材料组成和加工来满足耐用性和抗积体作用的阀门技术 心脏瓣膜的要求。我们的中心假设是：具有涡流发生器流量的超疏水性BMHV 控制技术将需要大大减少抗凝疗法。这在三个目标中进行了测试。目标1 专注于阐明传单组成和加工对血流相容性的影响 涂层的强度和血流兼容性。 AIM 2量化SH的心脏瓣膜血液动力学性能 使用VG BMHV识别理想的SH+VG构型，用于上等血液动力学和最小血液 损害。 AIM 3专注于理解SH与VG BMHV的体内体内血液相容性 学习。该建议由Lakshmi Prasad Dasi博士领导，他是一位训练有素的年轻调查员，具有专业知识 心脏阀工程和心血管生物力学，以及多种心脏阀技术的发明者 包括VG和新型生物分子聚合物小叶。多人是Kota博士，他是一位已建立的 超疏水材料专家； Popat博士的专业知识在于生物兼容和表面 纳米工程。合作社包括Brueur博士，Bark博士，Crestanello博士，Shinoka博士和Hor博士 经验丰富的团队在体内模型，血小板生物学，手术和成像方面具有专业知识。如果拟议的工作 证明具有VG BMHV的SH不需要抗凝，引起出色的血液动力学，并且是 耐用的R01赠款可能会导致几乎不需要或根本不需要的机械HV的突破性技术 抗凝。